Psoriasis - Advanced Therapies and Special Populations

Biologic Therapies in Psoriasis Introduction and Positioning in Treatment Biologic therapies are engineered drugs designed to target specific components of the immune system that drive psoriasis. These medications work by inhibiting particular cytokines or immune cells involved in the inflammatory cascade. Biologics represent a major advancement in treating moderate-to-severe psoriasis because they offer superior efficacy compared to traditional systemic medications for many patients. However, biologics are not first-line treatments. They're reserved as third-line therapy, recommended only after patients have failed other approaches. The typical progression follows this order: Topical agents (corticosteroids, vitamin D analogues) Phototherapy (UVB, PUVA) Non-biologic systemic drugs (methotrexate, cyclosporine, acitretin) Biologic therapies This stepwise approach exists because biologics, while highly effective, carry meaningful safety considerations that make them inappropriate as initial treatment. Safety Profile and Key Contraindications Biologic agents work by suppressing immune system components, which means they modestly increase infection risk. This is why they're not used lightly—the benefit must outweigh this immunosuppression burden. Certain patient populations should not receive biologics at all. Anti-TNF-α drugs (infliximab, adalimumab, golimumab, certolizumab pegol) are contraindicated in individuals who: Are carriers of chronic hepatitis B (biologics can reactivate the virus) Have HIV infection These contraindications exist because TNF-α plays a critical role in controlling these infections, and blocking it can have catastrophic consequences. Pregnancy presents another limitation. The safety of biologics during pregnancy hasn't been established, so European guidelines recommend avoiding them when pregnancy is planned. This is particularly important for women of childbearing age to discuss with their specialists. TNF-α Inhibitors Tumor necrosis factor-alpha (TNF-α) is a master regulator of inflammation in psoriasis. Blocking TNF-α was among the first successful biologic strategies, and these drugs remain highly effective, particularly for those with concurrent psoriatic arthritis. There are two structural types of TNF-α inhibitors: Monoclonal Antibodies (four agents that directly neutralize TNF-α): Infliximab Adalimumab Golimumab Certolizumab pegol These are laboratory-engineered antibodies that bind TNF-α and prevent it from interacting with its receptors. Fusion Protein: Etanercept works differently—it's a recombinant fusion protein made from TNF-α receptor extracellular domains. Think of it as a "decoy receptor" that traps TNF-α before it can bind to real immune cells. All TNF-α inhibitors are effective for moderate-to-severe psoriasis and psoriatic arthritis. Among the biologics overall, infliximab appears among the most effective for achieving skin clearance. Other Cytokine-Targeting Biologics Beyond TNF-α, researchers identified other critical inflammatory pathways in psoriasis. Newer biologics target these alternative pathways, offering additional options for patients. Interleukin-17 Inhibitors Ixekizumab and secukinumab block interleukin-17A (IL-17A), a key inflammatory molecule produced by T cells. These agents interrupt the inflammatory cascade at a different point than anti-TNF drugs. They're particularly valuable because they produce rapid skin clearance and represent an option for patients who failed TNF-α inhibitors. Interleukin-23 Inhibitors IL-23 is another critical cytokine in psoriasis. Multiple biologics target this pathway: Guselkumab and risankizumab specifically target IL-23 Ustekinumab blocks the p40 subunit shared by both IL-12 and IL-23, inhibiting both cytokines simultaneously These IL-23 inhibitors offer sustained efficacy with less frequent dosing requirements compared to some anti-TNF agents, which can improve patient adherence. Efficacy Ranking Current evidence indicates that infliximab, bimekizumab, ixekizumab, and risankizumab are among the most effective biologic therapies available for moderate-to-severe psoriasis. This information is important to understand that no single drug works for everyone—different patients respond best to different mechanisms. The Neutralizing Antibody Problem An important limitation of monoclonal antibody biologics is that patients can develop neutralizing anti-drug antibodies—antibodies against the therapeutic antibody itself. These anti-drug antibodies bind to the drug's antigen-binding site and block it from working, which can cause treatment failure and disease worsening. This phenomenon has been documented with: Infliximab Adalimumab Other monoclonal antibodies However, etanercept has not been associated with neutralizing antibodies. Why? Its fusion-protein structure appears to promote immune tolerance, meaning the body is less likely to mount an immune response against it. This is a clinically important distinction: if a patient fails infliximab due to antibody development, switching to etanercept (or to a non-TNF-α biologic) may restore efficacy. Special Populations Pediatric Psoriasis Anti-TNF agents are approved for severe psoriasis in children, with doses carefully adjusted based on body weight. The same safety considerations apply as in adults, but the evidence supporting their efficacy in pediatric populations is robust enough to warrant their use in severe cases. Pregnancy and Breastfeeding Acitretin (a non-biologic systemic retinoid) is absolutely contraindicated in pregnancy due to teratogenic effects. For biologics, the situation is more nuanced. Some biologics (particularly larger protein molecules like TNF-α inhibitors) have limited placental transfer, meaning the fetus receives minimal exposure. Under specialist guidance, certain biologics may be continued through pregnancy if the maternal benefit clearly outweighs theoretical risks. This requires careful individual assessment and should never be done without expert consultation. <extrainfo> Additional Agents Apremilast is an oral small-molecule inhibitor of phosphodiesterase-4 that reduces chronic inflammation in psoriasis. While technically not a biologic, it's increasingly used as an alternative to biologics in some patients who prefer oral medication or have contraindications to immune targeting. </extrainfo>